NEW YORK (GenomeWeb) – Piper Jaffray today downgraded shares of Hologic to a Neutral rating, saying that it sees limited opportunity for the company's shares to grow in value.

In a research note, analyst William Quirk downgraded Hologic from a previous Overweight rating but said the fundamental turnaround thesis remains intact.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.